TribLIVE

| USWorld


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

'Reverse vaccine' for diabetes passes test

Daily Photo Galleries

By The Los Angeles Times
Saturday, June 29, 2013, 6:57 p.m.
 

LOS ANGELES — A “reverse vaccine” that allows people with Type 1 diabetes to produce their own insulin has passed its first test with human subjects, according to a new study. The success points to a potential strategy for treating those in the early stages of the disease, experts said.

The therapy is designed to protect cells in the pancreas that make insulin, a hormone the body needs to convert sugars and starches into energy. In people with Type 1 diabetes, the immune system goes haywire and attacks those crucial insulin-producing cells for reasons that medical researchers don't understand.

Researchers dubbed the treatment a reverse vaccine because it suppresses the immune system, instead of stimulating it. As hoped, the experimental vaccine reduced the number of immune system “killer” cells that went on the attack.

“We're trying to turn off one specific immune response,” said Dr. Lawrence Steinman, an immunologist at Stanford University and senior author of the study published Wednesday in Science Translational Medicine.

About 1.25 million Americans have Type 1 diabetes.

 

 
 


Show commenting policy

Most-Read Nation

  1. White woman sues sperm bank for giving her donation from black man
  2. Murder charges dropped against sergeant who shot 2 unarmed Iraqi boys
  3. ER knew ill man visiting from Africa, sent him home
  4. Records show Kissinger pursued strategy to attack Cuba
  5. Mexico expected to free former Marine soon
  6. Head of Secret Service resigns
  7. West Virginia has tallied 45,500 storage tanks so far
  8. Secret Service chief resigns after security lapses
  9. MIT: Global Energy Use, CO2 May Double By 2100
  10. White man convicted of murder of black teenager in Jacksonville
  11. Girl missing for 12 years rescued in Mexico; mother arrested
Subscribe today! Click here for our subscription offers.